Search Result

Results for "

acid reflux

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (10) Apoptosis (10) Bacterial (22) Biochemical Assay Reagents (1) Calcium Channel (3) Cholecystokinin Receptor (1) Cholinesterase (ChE) (4) Cytochrome P450 (1) Dopamine Receptor (12) Drug Derivative (1) Drug Intermediate (1) Drug Metabolite (8) Endogenous Metabolite (1) Exosomes (4) HCV Protease (1) Histamine Receptor (7) Isotope-Labeled Compounds (16) mGluR (3) Neurokinin Receptor (1) Prostaglandin Receptor (1) Proton Pump (42) Reference Standards (17) Trk Receptor (3)
By Research Areas:	Cancer (33) Cardiovascular Disease (1) Endocrinology (25) Infection (1) Inflammation/Immunology (38) Metabolic Disease (13) Neurological Disease (10)

By Targets:

5-HT Receptor (10)

Apoptosis (10)

Bacterial (22)

Biochemical Assay Reagents (1)

Calcium Channel (3)

Cholecystokinin Receptor (1)

Cholinesterase (ChE) (4)

Cytochrome P450 (1)

Dopamine Receptor (12)

Drug Derivative (1)

Drug Intermediate (1)

Drug Metabolite (8)

Endogenous Metabolite (1)

Exosomes (4)

HCV Protease (1)

Histamine Receptor (7)

Isotope-Labeled Compounds (16)

mGluR (3)

Neurokinin Receptor (1)

Prostaglandin Receptor (1)

Proton Pump (42)

Reference Standards (17)

Trk Receptor (3)

By Research Areas:

Cancer (33)

Cardiovascular Disease (1)

Endocrinology (25)

Infection (1)

Inflammation/Immunology (38)

Metabolic Disease (13)

Neurological Disease (10)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15295

Vonoprazan Fumarate Maximum Cited Publications 6 Publications Verification TAK-438	Proton Pump	Metabolic Disease Cancer
Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H ⁺,K ⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .

HY-17021

Esomeprazole 3 Publications Verification (S)-Omeprazole; (-)-Omeprazole	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-100007

Vonoprazan Maximum Cited Publications 6 Publications Verification TAK-438 free base	Proton Pump Bacterial	Endocrinology Cancer
Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H ⁺,K ⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .

HY-B0656

Rabeprazole 5 Publications Verification LY307640	Proton Pump Apoptosis Bacterial	Inflammation/Immunology Cancer
Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H ⁺/K ⁺-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-17022

Esomeprazole magnesium trihydrate 1 Publications Verification (S)-Omeprazole magnesium trihydrate; (-)-Omeprazole magnesium trihydrate	Exosomes Proton Pump	Endocrinology Cancer
Esomeprazole magnesium trihydrate ((S)-Omeprazole magnesium trihydrate) is a potent and orally active H ⁺, K ⁺-ATPase inhibitor. Esomeprazole magnesium trihydrate has the potential for upper intestinal disorders and gastroesophageal reflux disease research . Esomeprazole magnesium trihydrate acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H ⁺-ATPases .

HY-B0656A

Rabeprazole sodium 5 Publications Verification LY307640 sodium	Proton Pump Apoptosis Bacterial	Inflammation/Immunology Cancer
Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H ⁺/K ⁺-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-17023

Esomeprazole sodium 2 Publications Verification (S)-Omeprazole sodium; (-)-Omeprazole sodium	Exosomes Proton Pump Bacterial	Endocrinology Cancer
Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H ⁺-ATPases . Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-17382

Metoclopramide 2 Publications Verification	5-HT Receptor Dopamine Receptor	Endocrinology
Metoclopramide is a potent antagonist of 5-HT₃ and dopamine D2 receptor, with IC₅₀s of 308 nM and 483 nM, respectively. Metoclopramide can be used for the research of nausea and vomiting, gastro-oesophageal reflux, and gastroparesis .

HY-100412

Linaprazan AZD0865	Proton Pump	Cancer
Linaprazan (AZD0865) can inhibit H+,K+ -ATPase in the stomach through K+ competitive binding, (IC₅₀: 1.0 ± 0.2 μM), it has a strong inhibitory effect on acid. Linaprazan (AZD0865) can be used for research on reflux esophagitis with oral activity .

HY-B1446

Esomeprazole magnesium 2 Publications Verification (S)-Omeprazole magnesium; (-)-Omeprazole magnesium	Exosomes Proton Pump	Endocrinology Cancer
Esomeprazole magnesium ((S)-Omeprazole magnesium) is a potent and orally active H ⁺, K ⁺-ATPase inhibitor. Esomeprazole magnesium has the potential for upper intestinal disorders and gastroesophageal reflux disease research . Esomeprazole magnesium acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H ⁺-ATPases .

HY-B0732

Itopride hydrochloride HSR803	Cholinesterase (ChE) Dopamine Receptor Bacterial	Neurological Disease
Itopride (HSR803) hydrochloride is a potent dopamine-2 antagonist and an acetylcholine esterase (AChE) inhibitor. Itopride hydrochloride enhances gastric motility through both antidopaminergic and anti-acetylcholinesterasic actions, can be used as a gastrointestinal prokinetic agent. Itopride can be used for researching gastro-esophageal reflux disease (GERD) .

HY-139557

Zastaprazan JP-1366	Proton Pump	Inflammation/Immunology
Zastaprazan (JP-1366) is a proton pump inhibitor and a potent potassium-competitive acid blocker. Zastaprazan can be used in the research of gastrointestinal inflammatory diseases or gastric acid-related diseases such as gastroesophageal reflux disease .

HY-B0160

Lafutidine FRG-8813	Histamine Receptor	Metabolic Disease Endocrinology
Lafutidine (FRG-8813) is a histamine H2-receptor antagonist (H₂RA), with proven gastric mucosal protective effects. Lafutidine can be used for the research of gastroesophageal reflux disease .

HY-139557A

Zastaprazan citrate JP-1366 citrate	Proton Pump	Inflammation/Immunology
Zastaprazan (JP-1366) citrate is a Proton pump inhibitor and potent potassium-competitive acid blocker. Zastaprazan citrate can be used in the research of gastrointestinal inflammatory diseases or gastric acid-related diseases such as gastroesophageal reflux disease .

HY-B0310

Nizatidine 2 Publications Verification	Histamine Receptor	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Nizatidine is a potent and orally active histamine H₂ receptor antagonist, can be used for the research of stomach and intestines ulcers. Nizatidine works by decreasing the secretion of gastric acid the stomach makes and prevent ulcers from coming back after they have healed in animal models .

HY-A0271

Aluminum Glycinate Dihydroxyaluminum Aminoacetate	Biochemical Assay Reagents	Inflammation/Immunology
Aluminum Glycinate (Dihydroxyaluminum Aminoacetate) is an organo-metallic compound and an antacid. Aluminum Glycinate can be used for the research of indigestion, acid reflux and ulcers .

HY-17021B

Esomeprazole potassium salt 2 Publications Verification (S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research .

HY-17382A

Metoclopramide hydrochloride hydrate 2 Publications Verification	5-HT Receptor Dopamine Receptor	Endocrinology
Metoclopramide hydrochloride hydrate is a potent antagonist of 5-HT₃ and dopamine D2 receptor, with IC₅₀s of 308 nM and 483 nM, respectively. Metoclopramide hydrochloride hydrate can be used for the research of nausea and vomiting, gastro-oesophageal reflux, and gastroparesis .

HY-B2089

Cinitapride	5-HT Receptor Dopamine Receptor	Neurological Disease Metabolic Disease
Cinitapride is a nonselective 5-HT1 and 5-HT4 receptors agonist and a 5-HT2 and D2 antagonist. Cinitapride can be used in functional dyspepsia (FD) and gastroesophageal reflux disease (GERD) research .

HY-13100

PF 03716556	Proton Pump	Metabolic Disease
PF 03716556 is a potent, selective, competitive and reversible acid pump (H ⁺,K ⁺-ATPase) antagonist with pIC₅₀s of 6.026, 6.038 and 6.009 for porcine, canine, and human recombinant gastric H ⁺,K ⁺-ATPase, respectively. PF 03716556 is inactive against other receptors, ion channels, and enzymes. PF 03716556 has the potential for gastroesophageal reflux disease research .

HY-100007A

Vonoprazan hydrochloride Maximum Cited Publications 6 Publications Verification TAK-438 hydrochloride	Proton Pump Bacterial	Infection Endocrinology Cancer
Vonoprazan hydrochloride, a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan hydrochloride inhibits H ⁺,K ⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan hydrochloride is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan hydrochloride can be used for eradication of Helicobacter pylori .

HY-W008614

Lansoprazole sulfone 1 Publications Verification AG-1813	Drug Metabolite Proton Pump	Metabolic Disease
Lansoprazole sulfone (AG-1813) is an orally active and selective inhibitor of H ⁺, K ⁺-ATPase. Lansoprazole sulfone can significantly stimulates gastric acid secretion by inhibiting H ⁺, K ⁺-ATPase. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .

HY-17021A

Esomeprazole magnesium salt (S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole magnesium salt has the potential for symptomatic gastroesophageal reflux disease research .

HY-17021S1

Esomeprazole-d3 (S)-Omeprazole-d₃; (-)-Omeprazole-d₃	Isotope-Labeled Compounds Proton Pump	Inflammation/Immunology Endocrinology Cancer
Esomeprazole-d₃ is deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-17021R

Esomeprazole (Standard) (S)-Omeprazole (Standard); (-)-Omeprazole (Standard)	Reference Standards Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole (Standard) is the analytical standard of Esomeprazole. This product is intended for research and analytical applications. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-B0732A

Itopride HSR803 free base	Cholinesterase (ChE) Dopamine Receptor Bacterial	Others
Itopride (HSR803 free base) is a potent and orally active dopamine-2 antagonist and an acetylcholine esterase (AChE) inhibitor. Itopride enhances gastric motility through both antidopaminergic and anti-acetylcholinesterasic actions, can be used as a gastrointestinal prokinetic agent. Itopride can be used for researching gastro-esophageal reflux disease (GERD) .

HY-B0656AS

Rabeprazole-d4 sodium LY307640-d4 sodium	Isotope-Labeled Compounds Proton Pump Apoptosis	Inflammation/Immunology Cancer
Rabeprazole-d₄ (sodium) is the deuterium labeled Rabeprazole sodium. Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-111313

JNJ-26070109	Cholecystokinin Receptor	Metabolic Disease
JNJ-26070109 is a high-affinity, competitive, orally bioactive, and selective cholecystokinin 2 (CCK2) receptor antagonist with good pharmacokinetic properties, with pK_is of 8.49, 7.99, and 7.70 for human, rat, and dog CCK2 receptors, respectively. The dual function of CCK2 receptors in regulating gastric acid secretion and growth of the gastrointestinal mucosa make this an attractive and novel target for the research of gastroesophageal reflux disease .

HY-15295R

Vonoprazan Fumarate (Standard) TAK-438 (Standard)	Proton Pump Reference Standards	Metabolic Disease Cancer
Vonoprazan (Fumarate) (Standard) is the analytical standard of Vonoprazan (Fumarate). This product is intended for research and analytical applications. Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .

HY-U00373

Revexepride 1 Publications Verification	5-HT Receptor Cytochrome P450	Neurological Disease
Revexepride is a highly selective 5-HT4 receptor agonist, and a potential inducer of CYP3A4 enzyme, used for the treatment of gastroesophageal reflux disease.

HY-101646

Saviprazole HOE-731	Proton Pump	Inflammation/Immunology
Saviprazole (HOE-731) is a H ⁺,K ⁺-ATPase inhibitor. Saviprazole inhibits gastric acid secretion. Saviprazole inhibits histamine- and dbcAMP-stimulated [ ¹⁴C]aminopyrine uptake, dbcAMP-induced oxygen consumption. Saviprazole can be used in research related to gastrointestinal diseases, such as gastric ulcers and acid reflux .

HY-17023R

Esomeprazole sodium (Standard) (S)-Omeprazole sodium (Standard); (-)-Omeprazole sodium (Standard)	Reference Standards Exosomes Proton Pump Bacterial	Endocrinology Cancer
Esomeprazole (sodium) (Standard) is the analytical standard of Esomeprazole (sodium). This product is intended for research and analytical applications. Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H ⁺-ATPases . Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-100007R

Vonoprazan (Standard) TAK-438 (Standard)	Reference Standards Proton Pump Bacterial	Endocrinology
Vonoprazan (Standard) is the analytical standard of Vonoprazan. This product is intended for research and analytical applications. Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H ⁺,K ⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .

HY-19865

Azeloprazole sodium	Proton Pump	Inflammation/Immunology
Azeloprazole sodium is a potent proton pump inhibitor (PPI). Azeloprazole sodium can be used for gastroesophageal reflux disease (GERD) research .

HY-17382B

Metoclopramide hydrochloride	5-HT Receptor Dopamine Receptor	Neurological Disease
Metoclopramide hydrochloride is a potent and orally active antagonist of 5-HT₃ and dopamine D2 receptor, with IC₅₀s of 308 nM and 483 nM, respectively. Metoclopramide hydrochloride can be used for the research of nausea and vomiting, gastro-oesophageal reflux, and gastroparesis .

HY-100412A

Linaprazan mesylate AZD-0865 mesylate	Proton Pump	Cancer
Linaprazan mesylate can inhibit H+,K+ -ATPase in the stomach through K+ competitive binding. (IC 50: 1.0 ± 0.2 μM), it has a strong inhibitory effect on acid. Linaprazan (AZD0865) mesylate can be used for research on reflux esophagitis with oral activity .

HY-110255

AZD 2066 1 Publications Verification	mGluR Calcium Channel Trk Receptor	Neurological Disease
AZD-2066 is a selective, orally active and blood-brain barrier-permeating mGluR5 antagonist. AZD 2066 activates the BDNF/trkB signaling pathway. AZD 2066 can be used in the research of neuropathic pain, major depressive disorder and gastroesophageal reflux disease .

HY-17023S

Esomeprazole-d6 sodium (S)-Omeprazole-d6 sodium; (-)-Omeprazole-d6 sodium	Isotope-Labeled Compounds Proton Pump	Others
Esomeprazole-d₆ sodium is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-B0656S

Rabeprazole-d4 LY307640-d₄	Isotope-Labeled Compounds Proton Pump Apoptosis	Inflammation/Immunology Cancer
Rabeprazole-d₄ is a deuterium labeled Rabeprazole. Rabeprazole is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-W008614S

Lansoprazole sulfone-d4 AG-1813-d₄	Isotope-Labeled Compounds Proton Pump Drug Metabolite	Inflammation/Immunology
Lansoprazole sulfone (AG-1813)-d₄ is the deuterium labeled Lansoprazole sulfone (HY-W008614). Lansoprazole sulfone, Lansoprazole (HY-13662) metabolite, is a H ⁺, K ⁺-ATPase inhibitor. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .

HY-B2089R

Cinitapride (Standard)	Reference Standards 5-HT Receptor Dopamine Receptor	Neurological Disease Metabolic Disease
Cinitapride (Standard) is the analytical standard of Cinitapride. This product is intended for research and analytical applications. Cinitapride is a nonselective 5-HT1 and 5-HT4 receptors agonist and a 5-HT2 and D2 antagonist. Cinitapride can be used in functional dyspepsia (FD) and gastroesophageal reflux disease (GERD) research .

HY-B0656AR

Rabeprazole sodium (Standard) LY307640 sodium (Standard)	Reference Standards Proton Pump Apoptosis Bacterial	Inflammation/Immunology Cancer
Rabeprazole (sodium) (Standard) is the analytical standard of Rabeprazole (sodium). This product is intended for research and analytical applications. Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H ⁺/K ⁺-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-Z3421S

Vonoprazan-d3 fumarate	Isotope-Labeled Compounds	Others
Vonoprazan-d₃ fumarate is the deuterium labeled Vonoprazan fumarate (HY-15295). Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .

HY-W703279

(R)-(+)-Pantoprazole sodium (R)-(+)-BY1023 sodium; (R)-(+)-SKF96022 sodium	Proton Pump	Inflammation/Immunology
(R)-(+)-Pantoprazole ((R)-(+)-BY1023) sodium is a proton pump inhibitor that can be used for the study of gastroesophageal reflux disease .

HY-19650

Pumosetrag Hydrochloride 1 Publications Verification MKC-733; DDP-733	5-HT Receptor	Metabolic Disease
Pumosetrag Hydrochloride (MKC-733; DDP-733) is an orally available 5-HT3 partial agonist developed for the treatment of irritable bowel syndrome and gastroesophageal reflux disease.

HY-B0310R

Nizatidine (Standard)	Reference Standards Histamine Receptor	Inflammation/Immunology Endocrinology Cancer
Nizatidine (Standard) is the analytical standard of Nizatidine. This product is intended for research and analytical applications. Nizatidine is a potent and orally active histamine H₂ receptor antagonist, can be used for the research of stomach and intestines ulcers. Nizatidine works by decreasing the secretion of gastric acid the stomach makes and prevent ulcers from coming back after they have healed in animal models .

HY-133716

Pantoprazole N-oxide	Drug Intermediate	Inflammation/Immunology
Pantoprazole N-oxide (Impurity-VI) is the impurity found during the Pantoprazole (HY-17507) production. Pantoprazole is an inhibitor for proton pump (PPI) that can be used for diseases related to excessive gastric acid, such as gastric ulcers and gastroesophageal reflux disease (GERD) .

HY-Z7660

Lansoprazole N-oxide	Drug Metabolite	Metabolic Disease Inflammation/Immunology
Lansoprazole N-oxide (Comound 2) is the overoxidized by-product found in the synthesis of the proton pump inhibitor Lansoprazole (HY-13662). Lansoprazole N-oxide is promising for research of duodenal and gastric ulcers, reflux oesophagitis, and Zollinger–Ellison syndrome .

HY-169833

BL 6341A	Histamine Receptor	Inflammation/Immunology
BL 6341A is an antagonist for histamine H2 receptor with K_i of 3.5-4.4 nM, that inhibits histamine-induced acid secretion and cAMP formation. BL 6341A can be used in research of gastric acid secretion related diseases, such as gastric ulcer or gastroesophageal reflux .

HY-17021C

Esomeprazole hemistrontium (S)-Omeprazole hemistrontium; (-)-Omeprazole hemistrontium	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole ((S)-Omeprazole) hemistrontium is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole hemistrontium has the potential for symptomatic gastroesophageal reflux disease research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N7541R

Antrodin A (Standard)	Microorganisms Ketones, Aldehydes, Acids Source Classification	HCV Protease Reference Standards
Metoclopramide (Standard) is the analytical standard of Metoclopramide. This product is intended for research and analytical applications. Metoclopramide is a potent antagonist of 5-HT3 and dopamine D2 receptor, with IC50s of 308 nM and 483 nM, respectively. Metoclopramide can be used for the research of nausea and vomiting, gastro-oesophageal reflux, and gastroparesis .

HY-N9808

Creoside III	Structural Classification Monophenols Rhodiola rosea Linn. Crassulaceae Phenols Plants Source Classification	Others
Creoside III is a glycoside compound, mainly used as a component of natural product libraries for potential activity screening studies in the field of natural product chemistry. Creoside III can be naturally extracted from the dried roots of Rhodiola crenulata (a plant of the genus Rhodiola in the Crassulaceae family) through methanol reflux extraction, column chromatography separation, and high-performance liquid chromatography purification .

HY-N17783A

Sanleng acid	Structural Classification Ketones, Aldehydes, Acids Magnoliaceae Oyama sieboldii (K. Koch) N. H. Xia & C. Y. Wu Plants Source Classification	Endogenous Metabolite
Sanleng acid is an unsaturated fatty acid compound that can be isolated from the hexane extract of Magnolia sieboldii (MsHE). MsHE can inhibit the expression of inflammatory mediators (such as COX-2) and pro-inflammatory cytokines (such as TNF-α, IL-1β), and increase the expression of tight junction proteins (claudin-4, claudin-5) to protect epithelial cell barrier function, thus exerting anti-inflammatory activity. Related compounds may be used in research related to reflux esophagitis (RE).

Cat. No.	Product Name	Chemical Structure

HY-17021S1

Esomeprazole-d3
Esomeprazole-d₃ is deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-B0656AS

Rabeprazole-d4 sodium

Rabeprazole-d₄ (sodium) is the deuterium labeled Rabeprazole sodium. Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-17023S

Esomeprazole-d6 sodium
Esomeprazole-d₆ sodium is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-B0656S

Rabeprazole-d4
Rabeprazole-d₄ is a deuterium labeled Rabeprazole. Rabeprazole is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-W008614S

Lansoprazole sulfone-d4
Lansoprazole sulfone (AG-1813)-d₄ is the deuterium labeled Lansoprazole sulfone (HY-W008614). Lansoprazole sulfone, Lansoprazole (HY-13662) metabolite, is a H ⁺, K ⁺-ATPase inhibitor. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .

HY-Z3421S

Vonoprazan-d3 fumarate

Vonoprazan-d₃ fumarate is the deuterium labeled Vonoprazan fumarate (HY-15295). Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .

HY-B0160S

Lafutidine-d10
Lafutidine-d₁₀ is deuterium labeled Lafutidine. Lafutidine (FRG-8813) is a histamine H2-receptor antagonist (H2RA), with proven gastric mucosal protective effects. Lafutidine can be used for the research of gastroesophageal reflux disease .

HY-17382S

Metoclopramide-d3
Metoclopramide-d₃ is deuterium labeled Metoclopramide. Metoclopramide is a potent antagonist of 5-HT3 and dopamine D2 receptor, with IC₅₀s of 308 nM and 483 nM, respectively. Metoclopramide can be used for the research of nausea and vomiting, gastro-oesophageal reflux, and gastroparesis .

HY-17021S

Esomeprazole-d3 sodium
Esomeprazole-d₃ (sodium) is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-17021S2

Esomeprazole-d3 potassium
Esomeprazole-d₃ potassium is deuterated labeled Esomeprazole (HY-17021). Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-W008614S1

Lansoprazole sulfone-13C6
Lansoprazole sulfone (AG-1813)- ¹³C₆ is ¹³C labeled Lansoprazole sulfone (HY-W008614). Lansoprazole sulfone, Lansoprazole (HY-13662) metabolite, is a H ⁺, K ⁺-ATPase inhibitor. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .

HY-B0656AS2

Rabeprazole-d4 potassium

Rabeprazole-d₄ potassium is deuterated labeled Rabeprazole potassium. Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an b>IC₅₀ of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-B0656S1

Rabeprazole-13C,d3

Rabeprazole-13C,d3 is a deuterated labeled Rabeprazole . Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H ⁺/K ⁺-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-B0656AS1

Rabeprazole-d3 sodium

Rabeprazole-d₃ sodium the deuterium labeled Rabeprazole sodium (HY-B0656A). Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an b>IC₅₀ of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-B0656AS3

Rabeprazole-13C,d3 sodium

Rabeprazole- ¹³C,d₃ (sodium) (LY307640- ¹³C,d₃ (sodium)) is ¹³C labeled Rabeprazole (sodium). Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H ⁺/K ⁺-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-B0732AS

Itopride-d6

Itopride-d₆ (HSR803-d₆ (free base)) is deuterium labeled Itopride. Itopride (HSR803 free base) is a potent and orally active dopamine-2 antagonist and an acetylcholine esterase (AChE) inhibitor. Itopride enhances gastric motility through both antidopaminergic and anti-acetylcholinesterasic actions, can be used as a gastrointestinal prokinetic agent. Itopride can be used for researching gastro-esophageal reflux disease (GERD) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks